New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Human rights, key and vulnerable populations Ethiopia received PEPFAR funding for work on stigma, discrimination and enabling legal environments. As a result of the USG stop-work order, all programmes ...

Health Cabinet Secretary Deborah Barasa has reaffirmed Kenya's dedication to providing uninterrupted care for individuals living with HIV, despite recent challenges stemming from a freeze in foreign ...

In the heart of the Cuban capital, the Dr. Cosme Ordoñez Carceller Teaching Polyclinic stands as a testament to the nation’s ...

In the first days of Donald Trump’s second term as United States president, he signed 2 executive orders that carry significant, immediate implications for patients who are lesbian, gay, bisexual, ...

Accurate and ethical journalism on HIV/AIDS plays a vital role in shaping public perceptions, encouraging behavioral change, and raising awareness. Misinformation or vague reporting, however, can ...

Invite the Ukrainian president to the heartland of America. Show him and the world that we categorically denounce the treatment he received.

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...